Osteoarthritis: current molecular biomarkers and the way forward
VB Kraus, MA Karsdal - Calcified tissue international, 2021 - Springer
The ultimate hope of researchers and patients is a pathway to development of treatments for
osteoarthritis to modify the disease process in addition to the symptoms. However …
osteoarthritis to modify the disease process in addition to the symptoms. However …
Synovial fluid biomarkers associated with osteoarthritis severity reflect macrophage and neutrophil related inflammation
Background To identify a synovial fluid (SF) biomarker profile characteristic of individuals
with an inflammatory osteoarthritis (OA) endotype. Methods A total of 48 knees (of 25 …
with an inflammatory osteoarthritis (OA) endotype. Methods A total of 48 knees (of 25 …
Osteoarthritis theranostics: extracellular vesicles and drug microfluidic screening platforms as innovative tools
D D'Arrigo - 2022 - boa.unimib.it
Despite the increasing incidence of knee osteoarthritis (OA), a world-leading cause of
disability, its early diagnosis is still unattainable. The current diagnostic process is mainly …
disability, its early diagnosis is still unattainable. The current diagnostic process is mainly …
SerpinA3N limits cartilage destruction in osteoarthritis by inhibiting macrophage-derived leucocyte elastase
A Latourte, S Jaulerry, A Combier, C Cherifi… - Annals of the Rheumatic …, 2024 - Elsevier
Objectives Inflammatory mediators such as interleukin 6 (IL-6) are known to activate
catabolic responses in chondrocytes during osteoarthritis (OA). This study aimed to …
catabolic responses in chondrocytes during osteoarthritis (OA). This study aimed to …